Real-world characteristics and outcomes of <i>ERBB2-</i> mutant NSCLC in Latin American patients (CLICaP)
This study demonstrated that ERBB2-mutant NSCLC is uncommon among Latin American patients. Despite the vast majority of patients being treated with chemo-immunotherapy (ICB) in the first line, the median rwOS was similar to that reported for non-oncogene-addicted NSCLC.
Authors
- Vladmir Cláudio Cordeiro de Lima (ORCID: https://orcid.org/0000-0003-3955-1101)
- Marcelo Corassa (ORCID: https://orcid.org/0000-0002-7707-8768)
- Jeremy Rodrigues (ORCID: https://orcid.org/0000-0002-9347-5026)
- Óscar Arrieta (ORCID: https://orcid.org/0000-0002-1164-3779)
- Jairo Zuluaga (ORCID: https://orcid.org/0009-0002-7534-5153)
- H. Freitas (ORCID: https://orcid.org/0000-0002-8415-073X)
- Leonardo Rojas-Mezarina (ORCID: https://orcid.org/0000-0003-0293-7107)
- Diego F. Chamorro (ORCID: https://orcid.org/0000-0003-1236-8120)
- Andrés F. Cardona (ORCID: https://orcid.org/0000-0003-3525-4126)
- Aline Fusco Fares (ORCID: https://orcid.org/0000-0002-7730-9810)
- Erick Figueiredo Saldanha (ORCID: https://orcid.org/0000-0001-7972-4244)
- Leonardo Gil-Santana
- Julien Soler
Institutions
- BC Cancer Agency (CA)
- University Health Network (CA)
- Princess Margaret Cancer Centre (CA)
- AC Camargo Hospital (BR)
- Beneficência Portuguesa de São Paulo (BR)
- Foundation for Clinical and Applied Cancer Research (CO)
- Instituto Nacional de Cancerología (MX)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-11-22
- DOI
- https://doi.org/10.1093/oncolo/oyae347
- Citations
- 2
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.88